24 May, 2017
Therefore 83% are positive. Puma Biotechnology has a one year low of $27.64 and a one year high of $73.27. $69.83's average target is 20.81% above currents $57.8 stock price.
Before that, quarter ending December 2016, Puma Biotechnology, Inc. also surprised analysts by beating the consensus estimate. The stock has "Neutral" rating by Citigroup on Thursday, September 3. Stifel Nicolaus upgraded the shares of PBYI in report on Wednesday, September 21 to "Buy" rating. The rating has been released in an analyst report on 23 May. Puma Biotechnology now has an average rating of "Hold" and a consensus target price of $62.64. On Tuesday, March 29 the stock rating was maintained by Credit Suisse with "Outperform". The firm has "Outperform" rating by Credit Suisse given on Thursday, January 21. JP Morgan maintained it with "Overweight" rating and $89 target in Tuesday, March 29 report. The company has market cap of $2.97 billion. The firm earned "Buy" rating on Tuesday, May 23 by Citigroup. BlackRock Inc. now owns 6,248 shares of the biopharmaceutical company's stock worth $419,000 after buying an additional 4,086 shares in the last quarter. Highland Capital Management LP acquired a new stake in shares of Puma Biotechnology during the fourth quarter worth about $1,136,000. Whole Foods Market Inc now has $11.36B valuation. The stock decreased 1.64% or $0.34 during the last trading session, reaching $20.45. About 30 shares traded. It has underperformed by 10.55% the S&P500.
The company's consensus rating is now Strong Buy, with 3 analysts rating it a Strong Buy, and 2 analysts rating it with a Hold. Puma Biotechnology Inc had 14 analyst reports since August 27, 2015 according to SRatingsIntel. The stock of RLJ Lodging Trust (NYSE:RLJ) earned "Buy" rating by Compass Point on Friday, November 6. The rating was downgraded by Zacks to "Hold" on Tuesday, September 22.
Investors sentiment decreased to 1.32 in 2016 Q4. Its down 0.17, from 1.49 in 2016Q3. Tekla Cap Mgmt Ltd Liability Corporation stated it has 260,200 shares. Vanguard Gp Incorporated holds 19.29 million shares. Alliancebernstein Ltd Partnership holds 0% or 39,140 shares. M&T Financial Bank invested 0% in RLJ Lodging Trust (NYSE:RLJ). Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical company's stock worth $163,000 after buying an additional 1,740 shares during the last quarter. AUERBACH ALAN H had sold 10,202 shares worth $339,064. $27,253 worth of Puma Biotechnology Inc (NASDAQ:PBYI) was sold by EYLER CHARLES R on Friday, January 20. Teachers Retirement Of The State Of Kentucky owns 61,874 shares. Cubesmart (NYSE:CUBE) was raised too.
Since January 20, 2017, it had 0 insider purchases, and 6 selling transactions for $690,596 activity. $76,208 worth of stock was sold by BRYCE RICHARD PAUL on Friday, January 20. CHARNAS ROBERT had sold 3,008 shares worth $95,755 on Wednesday, February 1.
ILLEGAL ACTIVITY NOTICE: "Puma Biotechnology Inc (PBYI) Shares Bought by Candriam Luxembourg S.C.A." was originally reported by BBNS and is owned by of BBNS. Lo Steven sold $76,108 worth of Puma Biotechnology Inc (NASDAQ:PBYI) on Friday, January 20. On average, analysts anticipate that Puma Biotechnology Inc will post ($8.12) EPS for the current year.
Investors sentiment decreased to 1.32 in 2016 Q4. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Puma Biotechnology by 253.3% in the third quarter. 22 funds opened positions while 53 raised stakes. Pnc Fincl Incorporated accumulated 1,000 shares or 0% of the stock. Glob X Limited Liability Company has invested 0% of its portfolio in Puma Biotechnology Inc (NASDAQ:PBYI). Citadel Advsrs Limited Com holds 0.01% or 467,945 shares in its portfolio. Credit Suisse Group AG set a $58.00 price target on shares of Puma Biotechnology and gave the stock a "buy" rating in a research note on Monday. Partner Fund Management L.P. owns 1.14 million shares or 0.99% of their United States portfolio. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/05/24/puma-biotechnology-inc-pbyi-rating-reiterated-by-citigroup-inc.html.
Puma Biotechnology Inc (NYSE:PBYI)'s stock had its "market perform" rating restated by research analysts at Cowen and Company in a research note issued on Monday.